| Variables |
Cases (N=26) |
Controls (N=78) |
| Gender |
Male |
10 (38%) |
29 (37.18%) |
| Female |
16 (62%) |
49 (62.82%) |
| Age |
Mean (±SD) |
42.04 (11.86) |
40.42 (9.96) |
| 15-30 |
6 (23%) |
10 (13%) |
| 31-45 |
12 (46%) |
45 (58%) |
| >46 |
8 (31%) |
23 (30%) |
| Body Mass Index |
<18.5 |
20 (77%) |
41 (53%) |
| ≥18.5 |
6 (23%) |
37 (47%) |
| Type of TB |
SPPTB |
10 (38%) |
55 (70%) |
| SNPTB |
3(12%) |
9 (12%) |
| EPTB |
13 (50%) |
14 (18%) |
| CD4+ cell count |
<50 |
15 (58%) |
22 (29%) |
| 51-100 |
4 (15%) |
18 (23%) |
| 100-200 |
6 (23%) |
19 (24%)) |
| >200 |
1 (4%) |
19 (24%) |
| Hepatitis B co-infection |
Yes |
7 (27%) |
4 (5%) |
| No |
19 (73%) |
74 (95%) |
| WHO HIV/AIDS stage |
Stage 3 |
13 (50%) |
64 (82%) |
| Stage 4 |
13 (50%) |
14 (18%) |
| ARV before TB treatment |
Yes |
19 (73%) |
50 (64%) |
| No |
7 (27%) |
28 (36%) |
| ARV regimen |
EFV based |
7 (37%) |
18 (36%) |
| NVP based |
11 (58%) |
29 (58%) |
| Boosted PIs based |
1 (5%) |
3 (6%) |
| Anti-TB Regimen |
2HRZES/1HRZE/5HRE |
2 (8%) |
9 (11%) |
| 2HRZE/4HR |
24 (92%) |
69 (88%) |
| Cotrimoxazole |
Yes |
18 (69%) |
46 (59%) |
| No |
8 (31%) |
32 (41%) |
|
